rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Theodore R. Schroeder

Director

Company insider

Files Form 4 as: Director, Phathom Pharmaceuticals; Director, Cidara Therapeutics; Chief Executive Officer, Nabriva Therapeutics; Director, Otonomy; Director, Collegium Pharmaceutical; Director, Hyperion Therapeutics; President, CEO, Cadence Pharmaceuticals; Director, Trius Therapeutics.

Every Form 4 they filed

In numbers

Trades disclosed
187
Buys
4
Sells
9
Bought
$323K
Sold
$1.7M
Companies
8
Companies where not an officer
6
First trade
22 Mar 2007
Last trade
19 May 2026
Last filed
21 May 2026

Companies traded

Where they are an officer
Nabriva TherapeuticsDirector, Officer · last 29 Jan 20233 buys · 0 sells
Cadence PharmaceuticalsDirector, Officer · last 19 Mar 20141 buy · 9 sells
Everywhere else they filed: board seats, 10% stakes, other companies
PHAT Phathom PharmaceuticalsDirector · Biotechnology · last 19 May 20260 buys · 0 sells
Cidara TherapeuticsDirector · Biotechnology · last 7 Jan 20260 buys · 0 sells
OtonomyDirector · last 21 Jun 20220 buys · 0 sells
COLL Collegium PharmaceuticalDirector · Pharmaceuticals · last 20 May 20200 buys · 0 sells
Hyperion TherapeuticsDirector · last 7 May 20150 buys · 0 sells
Trius TherapeuticsDirector · last 11 Sep 20130 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
19 May 2026filed 21 May 2026PHAT Phathom PharmaceuticalsBiotechnologySEC FORM 4 Code A—24,122 at $0.00filing
19 May 2026filed 21 May 2026PHAT Phathom PharmaceuticalsBiotechnologySEC FORM 4 Code A—24,122 at $0.00filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—450filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—20,500filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—11,100filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—550filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—550filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivativeSEC FORM 4 Code D—450filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivativeSEC FORM 4 Code D—550filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivativeSEC FORM 4 Code D—550filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivativeSEC FORM 4 Code D—550filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivativeSEC FORM 4 Code D—875filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivativeSEC FORM 4 Code D—875filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivativeSEC FORM 4 Code D—1,400filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivativeSEC FORM 4 Code D—2,125filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivativeSEC FORM 4 Code D—2,125filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivativeSEC FORM 4 Code D—20,500filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivativeSEC FORM 4 Code D—11,100filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—550filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—875filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Not placed13

Buys in green, sells in red, by the company’s sector.

Related people

Nobody else traded the same names lately.